Evotec (ETR:EVT) Trading Up 3.5% – What’s Next?

Shares of Evotec SE (ETR:EVT) were up 3.5% on Friday . The stock traded as high as €4.76 and last traded at €4.70. Approximately 869,582 shares changed hands during trading, a decline of 36% from the average daily volume of 1,360,000 shares. The stock had previously closed at €4.54.

Evotec Price Performance

The company has a 50 day simple moving average of €4.86 and a 200-day simple moving average of €5.50. The stock has a market cap of $856.85 million, a price-to-earnings ratio of -5.00, a P/E/G ratio of 0.98 and a beta of 1.24. The company has a current ratio of 1.68, a quick ratio of 2.97 and a debt-to-equity ratio of 55.38.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic.